Introduction
============

Antiretroviral therapy (ART) has played an important role in improving the prognosis and quality of life of HIV/AIDS patients, and in reducing the rate of disease progression and death.[@b1-hiv-6-109]--[@b3-hiv-6-109] It has also been reported that increased access to ART can reduce the risk of HIV transmission to sexual partners by 96%.[@b4-hiv-6-109]

ART adherence is a primary determinant of the effectiveness of this treatment, and is also considered a major predictor of survival among patients living with HIV/AIDS.[@b5-hiv-6-109] More than 95% adherence to ART is required in order to prevent the emergence of resistant HIV strains, obtain long-term HIV suppression, reduce destruction of CD4 cells, increase survival, and improve quality of life.[@b6-hiv-6-109],[@b7-hiv-6-109] However, poor ART adherence can create a dangerous public health problem and limit the effectiveness of available HIV treatments.[@b8-hiv-6-109] Poor ART adherence also leads to increased hospitalization rates, increased health care costs, reduced productivity, disruption of families and communities, and morbidity and mortality in low- and middle-income countries.[@b9-hiv-6-109] Moreover, second-line ART regimens can be up to six times more expensive than first-line regimens.[@b10-hiv-6-109] As some patients still show poor ART adherence, this factor remains a major obstacle in the fight against HIV/AIDS.[@b2-hiv-6-109],[@b7-hiv-6-109] Maintaining optimal ART adherence over a long period of time also poses significant challenges for both patients and health care providers.[@b9-hiv-6-109]

Factors affecting ART adherence include patient characteristics, ART regimen, clinical setting, social and environmental factors, and the relationship between patients and their health care providers.[@b6-hiv-6-109] Despite fears to the contrary, ART adherence is high among patients in some low- and middle-income countries.[@b11-hiv-6-109],[@b12-hiv-6-109]

HIV is a concentrated epidemic in Nepal, with an overall prevalence of 0.30% in the population aged 15--49 years.[@b13-hiv-6-109],[@b14-hiv-6-109] In 2011, approximately 50,200 adults and children were living with HIV in Nepal, of whom 28.5% were women and 58% were men of reproductive age.[@b14-hiv-6-109] The Government of Nepal started free ART and counseling services in 2004,[@b15-hiv-6-109] and by July 2012 ART coverage had increased to 26.1% (6,642 adults and 500 children) of 27,363 HIV-infected patients eligible for ART (CD4 ≤350) at 39 ART centers in 33 different districts.[@b16-hiv-6-109]

There are several ART regimens available in Nepal with acceptable antiretroviral potency. Generally, zidovudine (ZDV)/lamivudine (3TC)/neverapine (NVP), ZDV/3TC/efavirenz (EFV), tenofovir disoproxil fumarate (TDF)/3TC/NVP, TDF/3TC/EFV, stavudine (d4T)/3TC/EFV, and d4T/3TC/NVP are used as first-line regimens, while TDF/3TC/lopinavir boosted with ritonavir and didanosine/abacavir/lopinavir boosted with ritonavir are commonly used as the second-line regimens.[@b15-hiv-6-109] Previous studies in Nepal reported 85.5% ART adherence among attendees of 10 ART centers located in different districts,[@b17-hiv-6-109] 79% ART adherence at the Tribhuvan University Teaching Hospital in Kathmandu,[@b18-hiv-6-109] and 84% ART adherence in the far west of Nepal.[@b19-hiv-6-109]

Despite the high number of HIV-infected patients receiving ART in the Kathmandu District of Nepal, information on ART adherence and factors influencing adherence is lacking in this population. The present study aimed to estimate ART adherence among HIV-infected patients attending three ART centers in the Kathmandu District, and to determine the factors associated with ART adherence.

Materials and methods
=====================

Study settings and study population
-----------------------------------

The Kathmandu District has six ART centers. A multi-site cross-sectional study was conducted at three of them in January to February 2012: the Sukaraj Tropical and Infectious Disease Hospital, Bir Hospital, and the Tribhubhan University Teaching Hospital. The numbers of patients registered and receiving ART across these three centers was 2,240, 102, and 114, respectively. All patients aged 18 years or older who had received ART therapy for at least 3 months prior to study enrollment and were able to give informed consent were eligible for inclusion in the study. A sample size of 316 patients was calculated using formulas described previously,[@b20-hiv-6-109],[@b21-hiv-6-109] in order to estimate ART adherence with a relative precision of 5%. The number of patients included from each ART center was based on the proportion of patients registered and receiving ART therapy at each center.

Ethical approval was obtained from the Nepal Health Research Council and the National Center for AIDS and STD Control. All participants signed a written informed consent form.

Data collection and variables of interest
-----------------------------------------

Eligible patients were interviewed for 15--20 minutes by the first author and two ART counselors. The questionnaire used in the present study was adapted from an earlier study,[@b22-hiv-6-109] with slight modifications to fit the norms in Nepal. The questionnaire was translated into Nepali and verified by a second translator. The questionnaire was used to collect sociodemographic information, personal history of ART adherence, and socioeconomic status. Patients' medical records were used to collect information on CD4 cell counts and ART regimen.

Assessment of adherence
-----------------------

Adherence was assessed by asking patients to recall their intake of prescribed ART doses in the previous 7 days. In an attempt to minimize recall bias, patients were asked about adherence over the previous day, previous 3 days, and previous 7 days. Self-reported ART adherence was calculated as the ratio of the doses taken during the specific time-period to the total number of ART doses prescribed for the same time-period. The results were expressed as percentages. Patients were considered adherent if they reported taking 95--100% of their prescribed ART with a delay of no more than 1 hour in the previous 7 days.

Statistical analysis
--------------------

The information collected from patients was sorted, coded, and entered in a datasheet created in SPSS version 16 (SPSS Inc., Chicago, IL, USA). A double-data entry system was used to minimize errors in data entry. The explanatory variables were categorized as follows: age (continuous variable), sex (male/female), marital status (unmarried/ever-married), educational level (literate/illiterate), occupation (employed/unemployed), monthly income (tertiles), travel time to ART centers (continuous variable), alcohol use in the month preceding the interview (yes/no), illegal drug use in the 6 months preceding the interview (yes/no), and use of reminder tools to take ART (yes/no). The clinical characteristics included the latest available CD4 cell count (\>200/≤200 cells/mm^3^), ART initiation (\<24/≥24 months), adverse effects (yes/no), and the number of tablets taken daily (continuous variable).

Differences between adherent and non-adherent patients were tested using the Student's *t*-test and the chi-square test for continuous and categorical explanatory variables, respectively. The strength of association between explanatory variables and ART adherence was measured using logistic regression and was reported as odds ratios (OR) with 95% confidence intervals (CI). The OR associated with each explanatory variable was calculated first in a univariate model, then in an age- and sex-adjusted model, and finally in a multivariate model including all the variables. The variables with significant or borderline significant associations in the multivariate model were included in the final model. The criterion for statistical significance was set at *P*\<0.05.

Results
=======

Of the 316 participants, 64.6% (n=204) were men and 35.4% (n=112) were women. Most of the participants (n=308) were receiving standard first-line ART regimens. A total of 274 (86.7%) participants reported ART adherence, and of these, 268 claimed not to have missed a single dose. On the other hand, 42 (13.3%) participants reported non-adherence. The most frequently cited reasons for non-adherence were "simply forgot" (80%) and "busy schedule" (19%). Other reported reasons for non-adherence included being too sick (11%), to hide their status from their family and friends (4.7%), or adverse effects (4.7%). These percentages overlapped as multiple responses were possible.

[Table 1](#t1-hiv-6-109){ref-type="table"} shows the sociodemographic and clinical characteristics of the study sample by adherence status. Only travel time to ART centers (*P*\<0.001), alcohol use (*P*=0.026), illegal drug use (*P*=0.017), self-reported adverse effects (*P*=0.005), and use of reminder tools (*P*\<0.001) were significantly associated with adherence status. Almost 90% of the participants reported using some kind of reminder tool to take the medicine at the correct time ([Table 1](#t1-hiv-6-109){ref-type="table"}). Some of the most widely used reminder tools were mobile alarm, watch, and support from family members.

A total of 248 (78.5%) participants reported different health complaints that occurred in the month before interview, which could have been caused by either the HIV infection, or the ART ([Table 2](#t2-hiv-6-109){ref-type="table"}). Dizziness, skin rash, and vomiting were significantly more frequently reported among non-adherent participants (*P*\<0.005).

In univariate analyses ([Table 3](#t3-hiv-6-109){ref-type="table"}), non-adherence was significantly associated with the travel time to ART centers, alcohol use, illegal drug use, adverse effects, cost of travel to ART centers, and no use of reminder tools. A borderline significant association was observed with age. After adjusting for age and sex, the same variables remained significantly associated with non-adherence, and the adjusted ORs were almost unchanged. The final multivariate model included age, sex, travel time to ART centers, alcohol use, illegal drug use, adverse effects, and use of reminder tools ([Table 4](#t4-hiv-6-109){ref-type="table"}). A 1-year increase in age increased the odds of non-adherence by 4% (OR 1.04; 95% CI 1.00--1.09). An increase in travel time to ART centers of 1 hour was associated with a 38% increase in the odds of being non-adherent (OR 1.38; 95% CI 1.12--1.71). On the other hand, the odds of being non-adherent among participants with a history of illegal drug use was almost four times that of participants without a history of illegal drug use (OR 3.98; 95% CI 1.71--9.24), and the odds of non-adherence were highly increased in participants who reported adverse effects (OR 4.88; 95% CI 1.09--21.8). The odds of being non-adherent among participants who did not use reminder tools were 3.45 times those of participants who did use a reminder tool (OR 3.45; 95% CI 1.33--8.91).

Discussion
==========

To our knowledge, this is the first multi-site study to assess the factors associated with ART adherence among HIV-infected patients receiving free ART at ART centers in the Kathmandu District of Nepal. The overall self-reported ART adherence level for 1 week was 86.7%. Time taken to reach ART centers, self-reported adverse effects, illegal drug use, and not using reminder tools present barriers to ART adherence.

ART adherence in this study is consistent with previous, similar studies in Nepal, and is comparable to self-reported ART adherence in several other low- and middle-income countries.[@b3-hiv-6-109],[@b17-hiv-6-109],[@b19-hiv-6-109],[@b20-hiv-6-109] The slightly higher ART adherence in this study might be due the assessment of 7-day adherence. It is also possible that adherent patients are more likely to attend their outpatient appointments, and thus more likely to be included in this study sample. However, the 13% non-adherence observed in the present study constitutes a serious problem in a resource-limited country like Nepal, as the development of treatment resistance will lead to increased hospitalization rates, increased health care costs, reduced productivity, disruption of families and communities, and increased morbidity and mortality. The main reasons participants gave for non-adherence were simply forgetting to take ART and having a busy schedule, which is in accordance with previous findings.[@b12-hiv-6-109],[@b19-hiv-6-109],[@b23-hiv-6-109],[@b24-hiv-6-109]

The proportion of men in this study sample was approximately two-fold that of women, which is similar to the proportion of HIV/AIDS cases reported in Nepal.[@b14-hiv-6-109] Sex and marital status did not significantly affect ART adherence. This finding is in agreement with studies elsewhere,[@b12-hiv-6-109],[@b20-hiv-6-109],[@b23-hiv-6-109] but in contrast to a previous study in Nepal,[@b17-hiv-6-109] in which HIV-infected women were less likely to adhere to ART. Nevertheless, HIV-infected women in most low- and middle-income countries face several social, psychological, economical, and biological challenges which impact their ability to take medication. Therefore, the challenge to improve access to ART and ART adherence in women remains critical in these countries.[@b3-hiv-6-109]

The present study shows that ART adherence decreased significantly with increasing age. However, this finding contrasts with a study by Barclay et al, which showed that patients aged less than 50 years were two times more likely to be non-adherent,[@b25-hiv-6-109] and with studies that showed no association between age and ART adherence.[@b17-hiv-6-109],[@b19-hiv-6-109],[@b24-hiv-6-109],[@b26-hiv-6-109] Such variations could be related to differences between studies in terms of population sampling. Indeed, the number of persons aged 50 years and older living with HIV/AIDS is increasing due to ART.[@b27-hiv-6-109] Therefore, the influence of age may change over time and needs to be further elucidated. The results of this study provide evidence that difficult access to ART in the form of long travel time to ART centers can hinder ART adherence among HIV-infected patients in resource-limited countries. In accordance with this, two Indian studies[@b20-hiv-6-109],[@b23-hiv-6-109] and two African studies[@b12-hiv-6-109],[@b24-hiv-6-109] showed that traveling from distant places to ART centers was one of the barriers to ART adherence. It has been reported that, despite the extension of ART centers into different regions of Nepal, people living with HIV are unwilling to seek treatment at the nearest health institution due to fear of stigmatization.[@b17-hiv-6-109] In such situations, patients may choose to travel long distances to seek ART services, which may ultimately lead to less ART adherence because of time constraints. In Nepal, traveling long distances to receive treatment is common, and not surprisingly, transportation difficulties have often been reported to be a major hindrance to ART adherence.[@b3-hiv-6-109]

Health complaints such as dizziness, skin rash, and vomiting were more frequently reported by non-adherent than adherent participants. This study shows that health complaints due to HIV infection, or as an adverse effect of ART, are associated with non-adherence. This is consistent with findings of several other studies.[@b17-hiv-6-109],[@b19-hiv-6-109],[@b24-hiv-6-109] In addition, one meta-analysis showed that varying from mild to severe and from acute to chronic, adverse effects and toxicity of the complex ART drugs was an important reason for non-adherence.[@b28-hiv-6-109] The management of symptoms is a vital part of successful ART adherence. Hence, it is necessary to discuss all potential adverse effects with patients before they begin ART. Moreover, each patient must be assessed individually for readiness to adhere to complex ART regimens.[@b28-hiv-6-109]

In contrast to previous findings,[@b28-hiv-6-109] this study found no significant independent association between alcohol use and ART adherence. On the other hand, the high odds of non-adherence among participants with a history of illegal drug use are in agreement with previous studies.[@b3-hiv-6-109],[@b29-hiv-6-109]--[@b31-hiv-6-109] Patients with a history of substance use are significantly less engaged with their health care provider, and are likely to exhibit a higher rate of treatment refusal.[@b6-hiv-6-109],[@b28-hiv-6-109] Furthermore, psycho-social problems can be additional factors related to non-adherence among illegal drug users.

This study illustrates the strong association between the use of reminder tools and ART adherence. This supports earlier findings of 4.2-fold greater risk of non-adherence among patients who did not use any reminder tool.[@b8-hiv-6-109] In a review of ART adherence, Mills et al showed that reminders in the form of support from friends and family facilitates successful ART adherence.[@b32-hiv-6-109] In addition, disclosing one's HIV status to others had a positive influence on adherence.[@b3-hiv-6-109],[@b28-hiv-6-109]

Although many other potential variables were included in this study, they did not show consistent associations with ART adherence. The number of tablets taken per day was not associated with ART adherence in univariate or multivariate analysis. However, several other studies have shown that ART adherence decreases with an increasing number of tablets and number of daily doses.[@b20-hiv-6-109],[@b33-hiv-6-109] Nevertheless, various studies reported that despite new ART regimens with fewer tablets and daily doses, adherence remains a problem.[@b7-hiv-6-109],[@b33-hiv-6-109] Objective tools such as pill count, electronic pill caps, and other biological methods are needed in the evaluation of the association between the number of tablets and ART adherence.

Similar to previous studies,[@b17-hiv-6-109],[@b19-hiv-6-109],[@b34-hiv-6-109] no significant associations were found between education level, income, marital status, and adherence. Moreover, similar to most,[@b23-hiv-6-109],[@b24-hiv-6-109],[@b33-hiv-6-109] but not all[@b20-hiv-6-109] previous studies, the present study showed no significant association between the time since initiating ART and non-adherence.

ART adherence varies over time and between individuals. Therefore, using multiple measures, prospective and mixed studies, including qualitative and quantitative research from delivery sites run by both the public and private sector, are needed to assess the factors associated with ART adherence.

Strengths and limitations
-------------------------

The strengths of the study include the relatively large and representative sample of HIV-infected patients. Adherence was assessed for the 7 days prior to interview so that participants could accurately recall their behavior, thereby minimizing the chance of recall bias.

The findings may not form an adequate basis for generalization due to the limitations: ART adherence was self-reported, and was assessed in terms of missing doses during the previous 7 days. Other dimensions of ART adherence, such as whether participants took the ART in accordance with dietary instructions, were not explored. It should be mentioned that only patients who personally collected/refilled their ART at ART centers were included; patients whose ART was delivered to their home by volunteers were not approached. On the other hand, there might be other confounding factors that were not taken into account in this study. Self-reported information might have been influenced by recall bias and the social desirability effect, ie, patients' desire not to disclose non-adherence in order to present themselves as a good patient.[@b35-hiv-6-109] However, self-reported measures are commonly used in both research and clinical care because of their relatively low cost, ease of administration, and good correlation with indirect adherence measures, such as pill count.[@b36-hiv-6-109] Furthermore, this is a cross-sectional study, therefore the temporal relationship among the variables studied is unknown, and a causal relationship cannot be established.

Conclusion
==========

The ART adherence results in the present study are encouraging. The findings suggest that travel time to ART centers, self-reported adverse effects, and substance use present additional barriers to ART adherence. On the other hand, having reminder tools to take ART enhanced adherence. Interventions on the individual and community levels, such as community care centers and home-based care, need to be expanded at the village or district level to overcome these barriers. Moreover, health care providers should give clear instructions and proper counseling to patients in order to manage side effects. Patients reporting a history of illegal drug use should be targeted to enhance ART adherence. The use of different electronic devices such as watch and mobile phone should be encouraged as reminder tools to enhance ART adherence.
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###### 

Sociodemographic and clinical characteristics of HIV-infected patients in the Kathmandu District by ART adherence status, 2012

  Variables                                                               Total   Adherence N (%)[\*](#tfn1-hiv-6-109){ref-type="table-fn"}   Non-adherence N (%)[\*](#tfn1-hiv-6-109){ref-type="table-fn"}   *P*-value
  ----------------------------------------------------------------------- ------- ----------------------------------------------------------- --------------------------------------------------------------- -----------
  Age (years)                                                                                                                                                                                                 
   18--24                                                                 44      41 (93.0)                                                   3 (7.0)                                                         0.270
   25--34                                                                 87      78 (89.6)                                                   9 (10.4)                                                        
   35--49                                                                 148     125 (84.4)                                                  23 (15.6)                                                       
   \>50                                                                   37      30 (81.0)                                                   7 (19.0)                                                        
  Sex                                                                                                                                                                                                         
   Male                                                                   204     172 (84.3)                                                  32 (15.6)                                                       0.091
   Female                                                                 112     102 (91.1)                                                  10 (8.92)                                                       
  Marital status                                                                                                                                                                                              
   Unmarried                                                              68      59 (86.7)                                                   9 (13.3)                                                        0.945
   Married                                                                154     135 (87.6)                                                  19 (12.4)                                                       
   Divorced                                                               29      25 (86.2)                                                   4 (13.4)                                                        
   Widow/widowers                                                         65      55 (84.6)                                                   10 (15.4)                                                       
  Education level                                                                                                                                                                                             
   Illiterate                                                             56      48 (85.7)                                                   8 (14.3)                                                        0.848
   Primary education                                                      85      71 (83.5)                                                   14 (16.5)                                                       
   Secondary education                                                    99      88 (88.8)                                                   11 (11.2)                                                       
   Higher secondary                                                       61      54 (88.5)                                                   7 (11.5)                                                        
   University level                                                       15      13 (86.6)                                                   2 (13.4)                                                        
  Residence (region of Kathmandu)                                                                                                                                                                             
   Inside valley                                                          137     120 (87.5)                                                  17 (12.5)                                                       0.686
   Outside valley                                                         179     154 (86)                                                    25 (14)                                                         
  Occupation                                                                                                                                                                                                  
   Unemployment                                                           71      58 (81.6)                                                   13 (18.4)                                                       0.717
   Agriculture                                                            95      83 (87.3)                                                   12 (12.7)                                                       
   Labor work                                                             53      46 (86.7)                                                   7 (13.3)                                                        
   Business                                                               68      60 (88.2)                                                   8 (11.8)                                                        
   Office work                                                            26      24 (92.3)                                                   2 (7.7)                                                         
   Student                                                                3       3 (100)                                                     0 (0)                                                           
  Monthly income                                                                                                                                                                                              
   Lowest tertile                                                         99      83 (83.8)                                                   16 (16.2)                                                       0.054
   Middle tertile                                                         107     93 (86.9)                                                   14 (13.1)                                                       
   Highest tertile                                                        110     98 (89.1)                                                   12 (10.9)                                                       
  Family size                                                                                                                                                                                                 
   Nuclear                                                                208     158 (75.9)                                                  50 (24.1)                                                       0.746
   Joint                                                                  115     88 (23.5)                                                   27 (76.5)                                                       
   Live alone                                                             92      70 (76.0)                                                   22 (23.0)                                                       
  Mode of transmission                                                                                                                                                                                        
   Heterosexual                                                           242     212 (87.6)                                                  30 (12.3)                                                       0.947
   Shared needle                                                          40      34 (85.0)                                                   6 (15.0)                                                        
   Blood transfusion                                                      12      9 (75.0)                                                    3 (25.0)                                                        
   Unknown                                                                22      19 (86.3)                                                   3 (13.7)                                                        
  Cost of travel to ART center                                                                                                                                                                                
   Lowest tertile                                                         111     103 (92.7)                                                  8 (7.2)                                                         0.054
   Middle tertile                                                         99      84 (84.8)                                                   15 (15.2)                                                       
   Highest tertile                                                        106     87 (82.0)                                                   19 (18.0)                                                       
  Travel time to ART center (minutes)                                                                                                                                                                         
   ≤60                                                                    173     161 (93.0)                                                  12 (7.0)                                                        0.000
   \>60                                                                   143     113 (79.0)                                                  30 (21.0)                                                       
  Alcohol use[a](#tfn2-hiv-6-109){ref-type="table-fn"}                                                                                                                                                        
   No                                                                     268     238 (88.8)                                                  30 (11.2)                                                       0.026
   Yes                                                                    48      36 (75)                                                     12 (25)                                                         
  Illegal drug use[b](#tfn3-hiv-6-109){ref-type="table-fn"}                                                                                                                                                   
   Yes                                                                    43      27 (62.7)                                                   16 (37.3)                                                       0.017
   No                                                                     273     247 (90.4)                                                  26 (9.6)                                                        
  Reminder tools[c](#tfn4-hiv-6-109){ref-type="table-fn"}                                                                                                                                                     
   Yes                                                                    287     257 (89.5)                                                  30 (10.5)                                                       0.000
   No                                                                     29      17 (58.6)                                                   12 (41.4)                                                       
  ART initiation (month)                                                                                                                                                                                      
   \<24                                                                   166     148 (89.1)                                                  18 (10.9)                                                       0.178
   ≥24                                                                    150     126 (84.0)                                                  24 (16.0)                                                       
  CD4 cell count[d](#tfn5-hiv-6-109){ref-type="table-fn"} (cells/mm^3^)                                                                                                                                       
   \<200                                                                  56      44 (78.5)                                                   12 (21.6)                                                       0.193
   200--350                                                               148     130 (87.8)                                                  18 (12.2)                                                       
   \>350                                                                  99      87 (87.8)                                                   12 (12.2)                                                       
  Adverse effects                                                                                                                                                                                             
   Yes                                                                    248     208 (83.8)                                                  40 (16.2)                                                       0.005
   No                                                                     68      66 (97.0)                                                   2 (3.0)                                                         
  Number of tablets per day                                                                                                                                                                                   
   ≤3                                                                     237     202 (85.3)                                                  35 (14.7)                                                       0.180
   \>3                                                                    79      72 (91.1)                                                   7 (8.9)                                                         

**Notes:**

Row percentage;

alcohol use: alcohol use in past 1 month;

illegal drug use: illegal drug use in past 6 months prior to study;

reminder tools: use of any reminder tool to take ART;

CD4 count: latest available CD4 cell count.

**Abbreviation:** ART, antiretroviral therapy.

###### 

Distribution of health complaints among HIV-infected patients receiving ART in the Kathmandu District, 2012

  Health complaints   N[\*](#tfn7-hiv-6-109){ref-type="table-fn"} (%)   *P*-value[\*\*](#tfn8-hiv-6-109){ref-type="table-fn"}
  ------------------- ------------------------------------------------- -------------------------------------------------------
  Itching             72 (22.8%)                                        0.433
  Headache            43 (13.6%)                                        0.395
  Dizziness           40 (12.7%)                                        0.002
  Skin rash           39 (12.3%)                                        0.000
  Vomiting            39 (12.3%)                                        0.008
  Fatigue             34 (10.8%)                                        0.838
  Prolonged fever     32 (10.1%)                                        0.185
  Arthritis           23 (7.3%)                                         0.500
  Persistent cough    17 (5.4%)                                         0.438
  Anemia              16 (5.1%)                                         0.395
  Pain and numbness   15 (4.7%)                                         0.433
  Diarrhea            10 (3.2%)                                         0.525
  Others              13 (4.1%)                                         0.725
  Insomnia            9 (2.8%)                                          0.845

**Notes:**

Number overlap (participants could report more than one reason);

comparing frequency between adherent and non-adherent participants.

**Abbreviation:** ART, antiretroviral therapy.

###### 

Factors associated with non-adherence (univariate and age- and sex-adjusted) among HIV-infected patients in the Kathmandu District, 2012

  Variables                      Crude OR (95% CI)    Age and sex adjusted OR (95% CI)
  ------------------------------ -------------------- ----------------------------------
  Age                            1.03 (1.0--1.07)     1.03 (0.99--1.07)
  Sex                                                 
   Male                          1.89 (0.89--4.02)    1.87 (0.88--3.99)
   Female                        1                    1
  Marital status                                      
   Ever married                  1.00 (0.45--2.22)    0.62 (0.24--1.54)
   Unmarried                     1                    1
  Education level                                     
   Illiterate                    1.10 (0.48--2.54)    1.23 (0.52--2.86)
   Literate                      1                    1
  Occupation                                          
   Unemployed                    1.56 (0.76--3.19)    1.68 (0.81--3.47)
   Employed                      1                    1
  Income                                              
   Lower tertile                 1.57 (0.70--3.51)    1.81 (0.79--4.10)
   Middle tertile                1.22 (0.54--2.79)    1.32 (0.57--3.04)
   Higher tertile                1                    1
  Family                                              
   Without family                1.29 (0.61--2.72)    1.11 (0.52--2.38)
   With family                   1                    
  Cost of travel to ART center                        
   Lower tertile                 0.35 (0.14--0.85)    0.33 (0.14--0.82)
   Middle tertile                0.81 (0.39--1.71)    0.73 (0.34--1.57)
   Higher tertile                1                    
  Travel time to ART center      1.34 (1.13--1.61)    1.39 (1.16--1.67)
  Alcohol use                                         
   Yes                           2.64 (1.24--5.63)    2.76 (1.27--5.96)
   No                            1                    1
  Illegal drug use                                    
   Yes                           5.6 (2.68--11.78)    5.29 (2.49--11.24)
   No                            1                    1
  Use of reminder tools                               
   No                            6.04 (2.63--13.86)   6.04 (2.59--14.09)
   Yes                           1                    1
  ART initiation (month)                              
   ≥24                           1.56 (0.81--3.01)    1.24 (0.60--2.57)
   \<24                          1                    
  CD4 cell count (cells/mm^3^)                        
   ≤200                          1.82 (0.86--3.81)    1.89 (0.89--4.01)
   \>200                         1                    1
  Adverse effects                                     
   Yes                           6.34 (1.49--26.97)   6.99 (1.63--29.98)
   No                            1                    1
  Number of tablets per day                           
   \>3                           0.97 (0.59--1.59)    0.96 (0.59--1.56)
   ≤3                            1                    1

**Abbreviations:** OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy.

###### 

Factors associated with non-adherence (final multivariate model) among 316 HIV-infected patients in the Kathmandu District, 2012

  Variables                   Final multivariate model OR (95% CI)
  --------------------------- --------------------------------------
  Age                         1.04 (1.00--1.09)
  Sex                         
   Male                       2.19 (0.92--5.25)
   Female                     1
  Travel time to ART center   1.38 (1.12--1.71)
  Alcohol use                 
   Yes                        2.26 (0.93--5.44)
   No                         1
  Illegal drug use            
   Yes                        3.98 (1.71--9.24)
   No                         1
  Adverse effects             
   Yes                        4.88 (1.09--21.80)
   No                         1
  Use of reminder tools       
   No                         3.45 (1.33--8.91)
   Yes                        1

**Abbreviations:** OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy.
